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We evaluated the influence of an antioxidant and zinc nutritional
supplement [the Age-Related Eye Disease Study (AREDS) formu-
lation] on delaying or preventing progression to neovascular AMD
(NV) in persons with age-related macular degeneration (AMD).
AREDS subjects (n = 802) with category 3 or 4 AMD at baseline
who had been treated with placebo or the AREDS formulation
were evaluated for differences in the risk of progression to NV
as a function of complement factor H (CFH) and age-related
maculopathy susceptibility 2 (ARMS2) genotype groups. We used
published genetic grouping: a two-SNP haplotype risk-calling
algorithm to assess CFH, and either the single SNP rs10490924
or 372_815del443ins54 to mark ARMS2 risk. Progression risk was
determined using the Cox proportional hazard model. Genetics–
treatment interaction on NV risk was assessed using a multiitera-
tive bootstrap validation analysis. We identified strong interaction
of genetics with AREDS formulation treatment on the develop-
ment of NV. Individuals with high CFH and no ARMS2 risk alleles
and taking the AREDS formulation had increased progression to
NV compared with placebo. Those with low CFH risk and high
ARMS2 risk had decreased progression risk. Analysis of CFH and
ARMS2 genotype groups from a validation dataset reinforces this
conclusion. Bootstrapping analysis confirms the presence of a ge-
netics–treatment interaction and suggests that individual treat-
ment response to the AREDS formulation is largely determined
by genetics. The AREDS formulation modifies the risk of progres-
sion to NV based on individual genetics. Its use should be based on
patient-specific genotype.
ophthalmology | macular degeneration | bootstrap validation | genetic
effect modification | statistical interaction
Age-related macular degeneration (AMD) is the leadingcause of visual disability in the industrialized world and the
third leading cause globally (1). Approximately 11 million indi-
viduals are affected with AMD in the United States, with a global
prevalence of 170 million, projected to increase to 288 million by
the year 2050. In 2009, the direct annual health care cost due to
AMD in the US was $4.6 billion (2).
AMD preferentially damages the macula, the central region of
the retina (3). AMD may be classified as early, intermediate, or
advanced, based on macular phenotype and visual acuity.
Blindness due to AMD is typically caused by the advanced stage
of the disease, which takes two principal forms. Neovascular
AMD (NV) refers to pathologic angiogenesis and its sequelae
and is characterized by relatively rapid loss of central vision.
Central geographic atrophy (GA) refers to localized atrophy of
central macular tissue and associated structures and is charac-
terized by a more gradual progressive loss of vision (3). The risk
of developing AMD is influenced by a complex interaction of
age, environment, and genetics. Genetic factors add to retinal
phenotype as predictors of advanced disease (4). Polymorphisms
in the complement factor H (CFH) and age-related maculopathy
susceptibility 2 (ARMS2) genes have the greatest impact on the
progression to advanced AMD (5–7).
The Age-Related Eye Disease Study (AREDS) concluded that
the AREDS formulation, a combination of high-dose antioxidants
(β-carotene, vitamin C, and vitamin E) and high-dose zinc, re-
duced the 5-y risk of progression from intermediate to advanced
age-related macular degeneration by 25% (8). Although advanced
AMD was defined in the AREDS as either NV or central GA, the
demonstrated reduction in progression to advanced AMDwas due
to a decrease in progression to NV and not by decreased pro-
gression to central GA, even after long-term evaluation (8, 9).
Multiple publications have evaluated the influence of genetic
risk on the response to the AREDS formulation (10–13). These
analyses are all derived from various data subsets from the
AREDS, the only placebo-controlled, long-term study of the effect
of nutritional therapy on AMD progression. These publications
address the phenomenon of interaction, a statistical term indicating
that the effect of one independent variable on a dependent variable
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is influenced by the level of a second independent variable. Many
of these publications have looked for a significant interaction be-
tween genetics and the AREDS formulation on AMD progression.
Controversy exists based on methodology and subset of patients
analyzed. In particular, Awh et al. (12) have stated that genotype
groups, defined by combinations of variants in the CFH and
ARMS2 genetic regions, can identify individuals who benefit greatly
from treatment with the AREDS formulation, as well as those who
derive no benefit, or are maybe even harmed. Chew et al. (14)
found no evidence of genetic influence on response to AREDS
formulation treatment. These analyses included both central GA
and NV as clinical end points. Earlier work by Chew et al. (8, 9)
noted that AREDS supplements do not delay or prevent central
GA, and Seddon et al. (11) found a significant interaction between
genetics and AREDS formulation treatment on NV progression
but not for central GA. AREDS formulation treatment delays or
prevents progression only to NV, and the inclusion of patients who
progress to central GA in these analyses dilutes the data and may
obscure a significant interaction.
Because the subsequent AREDS2 was designed and conducted
without a placebo control arm, no large dataset exists to validate
either the primary or any secondary findings from the AREDS. In
this study of an expanded dataset from the AREDS, we perform a
validation analysis of the interaction of genetics and treatment
using bootstrapping, a statistical resampling technique. We used
0.632 bootstrapping to compare the predictive accuracy of models
of NV progression risk that may or may not include interaction of
genotype group with AREDS formulation treatment. By aggregate
analysis of multiple (thousands) random discovery and validation
sets generated through resampling of the main dataset, predictors
of NV progression can be accurately identified by observing their
incremental contribution to model accuracy. This well-established
computational method allows powerful statistical determination of
the reproducibility of prediction models (15). Validation using the
bootstrapping technique can help distinguish false associations,
resulting from overfitting or multiple testing, from true ones.
Bootstrapping accurately identifies true determinants of clinical
outcome better than analysis of a single dataset (15–17).
Materials and Methods
Subjects. Subjects were derived from the AREDS population. Study procedures
have been reported previously (8). Subjects were characterized by AREDS in-
vestigators at enrollment and during half-yearly follow-ups using retinal im-
ages classified by a central reading center. This allowed determination of the
time interval from study enrollment to AMD progression to either central GA
or NV (8). The AREDS investigators randomized subjects to receive placebo,
zinc (80 mg daily), antioxidants (β-carotene, 15 mg; vitamin C, 500 mg; and
vitamin E, 400 IU), or both zinc plus antioxidants. Our analyses are restricted to
subjects randomized to placebo or to zinc plus antioxidants (the “AREDS
formulation”). Subjects who experienced progression events at 2 y or less from
study enrollment were not considered in this analysis, since these events were
unlikely a result of the assigned treatment (9). The complete phenotype data
were provided through the database of Genotypes and Phenotypes (dbGAP)
under an investigator agreement with one of the authors (R.K.). This work was
approved by the University of Toronto Research Ethics Board. Informed
consent was provided by all study subjects upon enrollment in the AREDS.
Genetic Datasets. We assembled genotyping data from three separate sample
sources: (i) Targeted sequencing was performed by others on 3,340 AMD
samples from the Michigan, Mayo, AREDS, Pennsylvania (MMAP) sample set.
Short-read sequences were matched to the Genome Reference Consortium
build 37 (GRCh37) assembly before being deposited into the NIH’s dbGaP
database that has been made available through an investigator agreement
(R.K.). We obtained the aligned sequences from dbGaP using the NIH’s sra-
toolkit (version 2.5.4). The read sequences for the CFH (chromosome 1) and
ARMS2 (chromosome 10) loci were processed using the Samtools package
(www.htslib.org) to deduce unphased genotypes at single-nucleotide poly-
morphic variants in the complement factor H genomic region (rs1061170,
rs3766405, and rs412852) and one SNP (rs10490924) in the age-related mac-
ulopathy sensitivity 2 region (www.htslib.org). This yielded genotypes for
2,003 AREDS samples of all presenting grades and treatment groups. (ii )
Genotyping data were generated from 1,390 AREDS DNA samples purchased
from the Coriell Institute (13). Beckman Coulter Genomics according to Good
Laboratory Practices performed genotyping at CFH and ARMS2 using bi-
directional sequencing. (iii) Genotypes at CFH rs2755405 and rs412852 and
ARMS2 rs10490924 loci from 534 cases referenced by Chew et al. and collab-
orators (18, 19) were made available to our group in May 2017 from the
National Institutes of Health Office of Research Integrity and Compliance.
Of these samples, we eliminated duplicates and all MMAP samples obtained
from subjects who were not part of the AREDS. This resulted in 1,626 samples. Of
these, 802 were from subjects randomized to treatment with either placebo or
the AREDS formulation, which we refer to as the “expanded” dataset. Of these
802 subjects, 299 had not been part of the prior Awh et al. (12) published anal-
yses. This subgroup of 299 subjects is referred to as the “unique” dataset. Subject
distribution between treatment and genetic groups is provided in Fig. 1. AREDS
ID/ID2 numbers for each study subject are included as SI Appendix, Table 1.
Marker Selection. To analyze the common genetic variability of the CFH locus, we
selected rs3766405 and rs412852 to tag the twomajor CFH haplotypes as has been
done previously (12, 13). We defined the two SNP “high-risk” haplotypes to be
rs3766405 CC/rs412852 CC, the average-risk haplotype to be rs3766405 CT/rs412852
CT or rs3766405 CC/rs412852 CT, and the “low-risk” haplotypes to be all other
combinations. The derivation of these groups has been described previously (12).
Weprespecified genotypegroups in themanner described byAwhet al. (12).
Briefly, we determined the number of AMD risk alleles at CFH and ARMS2 for
each subject. Given the relative rarity of homozygous CFH low-risk alleles and
ARMS2 homozygous high-risk alleles, subjects homozygous for these rare al-
leles were grouped with subjects heterozygous for the corresponding risk al-
leles (12). Genotype group (GTG) 1 was composed of subjects with low/
intermediate CFH and no ARMS2 risk alleles (C01A0). GTG2 subjects had high
CFH and no ARMS2 risk alleles (C2A0). GTG3 subjects had low/intermediate
CFH and one or two ARMS2 risk alleles (C01A12). GTG 4 subjects had high CFH
and one or two ARMS2 risk alleles (C2A12). This is summarized in Table 1.
Clinical Outcome Determination. Subjects in the AREDS cohort varied based on
baseline AMD status. Subjects were classified based on the severity of AMD in
each eye. We restricted this analysis to subjects with category 3 or 4 AMD at
baseline, which are the subgroup of subjects for whom the AREDS formu-
lation was reported beneficial in the original AREDS analysis (9).
Fig. 1. Distribution of subjects by treatment and genotype group in dis-
covery, validation, and combined sets. PBO, placebo.
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Progression of each subject to either NV or central GA was determined
through data fromwithin dbGaP tables pht000375.v1.p1.c and pht000376.v1.
p1.c1, which provide detailed disease phenotype data for each timed study
visit. Definitions for progression to NV or to central GA are documented in
“AREDS dbGAP Data Tables: A User’s Guide” (20) or in published work from
the AREDS retinal image reading center (21). NV was indicated by a score of
11 or 12 in the AMDSEV[R/L]E data field, while central GA by a score of 10 or
12. We have censored observations at 7 y, as has been done in most previous
analyses of these data. Since fundus photographs were taken starting at
year 2 (20), we also eliminated any progression events reported within the
first 2 y, as these were unlikely to be the result of treatment assignment.
Statistical Analysis. The main analyses done in this paper were performed with
the expandeddataset, tomaximize statistical power.Wenote that the selection
of particular biomarkers and the composition of genotype groupings in Awh
et al. (12) were based on a subset of this expanded dataset. This fact could
potentially bias our results, causing us to overestimate significance. To guard
against this possibility, we have replicated the main results using just the
unique set, that is, those subjects who were not used in Awh et al. These
validation analyses appear in Analysis Restricted to the Unique Set.
Analyses of genetic and nutritional supplement effects and their interactions
were done using a Cox proportional hazards model that was adjusted for the
following known potential confounders: age at enrollment, sex, and smoking
status. Body mass index was not used as a confounder because of a sizable
number of missing records. All analysis was done using R statistical software
(https://cran.r-project.org) and the rms package (biostat.mc.vanderbilt.edu/wiki/
Main/Rrms). Hazard ratios (HRs) and P values were calculated using the contrast()
function in the rms package to compare specific groups. All statistical code used
in this paper is included as SI Appendix. This permits the reproduction of all
statistical calculations by any investigator with access to AREDS phenotype
and genotype datasets for subjects identified in SI Appendix, Table 1.
Bootstrap Resampling Validation of Interaction. To evaluate the presence of a
genetics–treatment interaction, we used the bootstrapping technique (22,
23). This technique of random sampling with replacement provides a con-
venient, though computationally intensive, method to make population-
wide statistical inferences (Fig. 1). A version called “0.632 bootstrap” is
widely used to validate clinical prediction models (24–26). In our setting, the
bootstrap exercise was used to assess whether the previously proposed hy-
pothesis of genetics–treatment interaction was a spurious finding or had
clinical validity (12). The bootstrap results in this paper were obtained using
the R package “pec” (prediction error curves), which uses 0.632 bootstrap
for predictive analysis of time-to-event data (27). The statistical models be-
hind the methods used in the pec package utilize the inverse probability of
censoring weighted estimators to deal with censored time-to-event data.
We compared event prediction accuracy in subjects using models with and
without a genetics–treatment interaction. This approach allows validation of
this interaction effect by observing whether prediction models which include the
interaction predict the outcome of subjects better than models that do not.
Because the purpose of this bootstrap analysis is to test the hypothesis that a
genetics–treatment interaction exists, we limited our analysis to the two geno-
type groups found to be most differently affected by AREDS formulation treat-
ment: individuals GTG2 (n = 107) and GTG3 (n = 305), for a total of 412 subjects
from the expanded set. In each of 100,000 iterations, 412 subjects meeting these
criteria were randomly selected with replacement from the 412-subject set. Three
Cox models were built using these discovery sets. Study subjects not selected
became a paired iteration-specific bootstrap validation sample. On average, 63%
of subjects would be selected randomly at least once as a discovery set, for Cox
modeling, leaving 37% for bootstrap validation. Three models were considered:
(i) the base model, which considers genetics, sex, smoking, and age as covariates;
(ii) the additive model, which considers the presence of AREDS formulation
treatment in addition to the base model covariates and assumes that the effect
of AREDS formulation treatment is not influenced by genetics; and (iii) the in-
teraction model, which considers the same covariates as the additive model but
allows for the interaction of AREDS formulation treatment and genetics (Table 2).
We also performed the same bootstrap model comparison on all four genotype
groups and for subjects found only within the unique set (SI Appendix, Table 1).
Thepredictiveaccuracyofeachmodelwasexpressedas the concordance index (C
index) (Fig. 2). For a pair of subjects randomly selected from a bootstrap validation
set, if one subject experienced progression before the other subject, and themodel
being evaluated correctly predicted this, that pair of subjects is considered “con-
cordant.” The percentage of concordant pairs in each validation set with at least
one event and no event-time “ties” is the C index. One C index is generated for
each bootstrap iteration and the result is averaged over all 100,000 iterations. This
procedure was repeated for a number of time points within the AREDS follow-up
time range. For convenience, the C index was converted to a Somers’ Dxy measure
using the formula Dxy = 2*(C index − 0.5). Both the C index and Somers’ Dxy
provide the same information as the area under a receiver operator characteristic
curve in uncensored data, but Somers’ Dxy corrects for random guessing: It is
positive if model predictions are better than random guessing, with a maximum
value of 1.00 indicating perfect concordance. To generate approximate pointwise
95% confidence intervals, we used quantiles from a block-bootstrap approach (23),
where we considered 100,000 bootstrap replications to be 1,000 realizations of
bootstrap curves, with each curve based on 100 replications.
Results
Sample Set. Data derived from purchased Coriell AREDS DNA
and dbGAP MMAP sequencing and data provided by the NIH
Office of Research Integrity and Compliance allowed us to identify
802 AREDS subjects (the expanded dataset) with AREDS cate-
gory 3 or 4 AMD at study entry treated with either the AREDS
formulation or placebo. Of these, we designate 299 subjects not
used in the previous Awh analyses as the unique dataset.
Table 1. Previously published genetic grouping using CFH and ARMS2 markers (12)
Genotype group Subjects (802) CFH risk rs3766405/rs412852 ARMS2 risk rs10490924
GTG1 229 Low/intermediate-risk all except CC/CC Low-risk GG
GTG2 107 High-risk CC/CC Low-risk GG
GTG3 305 Low/intermediate-risk all except CC/CC High-risk GT/TT
GTG4 161 High-risk CC/CC High-risk GT/TT
The number of individuals in each group among 802 subjects receiving placebo or AREDS formulation
is shown.
Table 2. Covariates in three bootstrap models
Bootstrap model Description
Base Considers the effect of genetics and other confounders. This model assumes that
progression to NV is not different in subjects treated with AREDS vs. placebo.
Additive Considers the covariates of the base model, as well as the effect of treatment with
the AREDS formulation. Does not allow interaction between genetics and AREDS
formulation treatment.
Interaction Considers the covariates of the additive model, and allows interaction between
genetics and AREDS treatment. Assumes that the response to treatment may differ
among genotype groups.
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Subjects receiving AREDS formulation treatment and those
receiving placebo were balanced with respect to the distribution
of CFH or ARMS2 risk alleles, smoking, education level, sex, and
age, reflecting random AREDS treatment assignment (data
not shown).
CFH and ARMS2 and AREDS Formulation Association with NV and
Central GA. We first performed an additive Cox regression to
evaluate the effect of CFH and ARMS2 alleles on the risk of
progression to neovascular AMD and on the risk for developing
central geographic atrophy within the expanded set of 802 sub-
jects. The adjusted HR for NV and central GA for subjects
having two high-risk CFH alleles compared with intermediate-
and low-risk subjects was 1.72 (P = 0.0024) and 1.26 (P = 0.26),
respectively. Those with high-risk ARMS2 genotypes had an HR
of 2.76 (P < 0.0001) for developing NV and an HR of 1.65 (P =
0.03) for developing GA.
Interaction of Genetics and Treatment Group with Progression to NA or
GA.We used the Cox regression function in data from 802 subjects
in the expanded dataset to examine statistical interactions between
treatment group (AREDS formulation or placebo) and CFH and
ARMS2 genotype group on the progression to NV and central GA
separately. Strong interaction was seen between CFH and ARMS2
risk alleles and AREDS formulation treatment with NV as a
progression end point (Table 3). No significant interaction was
observed between AREDS formulation treatment and CFH or
ARMS2 risk alleles on progression to central GA. Given these
observations, we confined subsequent analyses of genetics–treat-
ment interaction to its effect on progression to NV.
To test the clinical utility of these observations for making
individual treatment recommendations, we generated Cox model
adjusted survival curves which control for age, sex, and smoking
as covariates. For subjects with high CFH risk alleles and without
ARMS2 risk alleles (GTG2), a significant increase in the rate of
progression to NV is observed among those treated with the
AREDS formulation compared with placebo (HR = 2.9, P =
0.018) (Fig. 3, Left). For subjects with the opposite genetic risk
pattern, low CFH and high ARMS2 risk alleles (GTG3), a
marked decrease in the rate of progression to NV was observed
among those treated with the AREDS formulation vs. placebo
(HR = 0.50, P = 0.008) (Fig. 3, Right).
Bootstrapping Validation. To further test for the presence of a
genetics–treatment interaction effect in the AREDS population,
we evaluated the relative predictive accuracy of models of pro-
gression risk for NV that either include an interaction effect or do
not. The pointwise 95% confidence bands strongly suggest the
superior predictive ability of the interaction model over the other
two models across later time points (4.5 y and beyond). Equal
predictive performance was observed for the base model (genetics
with demographics) and the additive model, which adds knowl-
edge of AREDS formulation treatment but without allowing ge-
netic interaction. This suggests a negligible average treatment
effect of the AREDS formulation when interaction with genetics
is not considered (Fig. 4). Similar bootstrap results generated both
from the full expanded set of 802 cases of all four genotype groups
and from subjects in the unique set are provided (SI Appendix,
Figs. 1 and 2).
Analysis Restricted to the Unique Set. A concern of data overfitting
has been raised in response to publications by Awh et al. (12, 18,
19) that first described the relationship between nutritional
treatment and CFH/ARMS2 genotype combinations. Selection of
particular biomarkers and the composition of genetic groupings
may have resulted in inflated statistical significance. As a valida-
tion analysis, we replicated main genetics–treatment interaction
findings in subjects from the unique set, consisting of subjects who
were not part of any previous analysis by Awh et al. (12, 18).
A Cox regression analysis of the unique dataset (placebo or
AREDS formulation-treated; n = 299) was adjusted for age, sex,
and smoking, in the same fashion as in the expanded set. Due to
the comparatively small sample size, time censoring was not per-
formed to maximize the number of NV progression events avail-
able for analysis. We observe that subjects with high CFH risk
alleles and no ARMS2 risk alleles (GTG2; n = 82) have a signif-
icant increase in progression risk if treated with the AREDS
formulation vs. placebo (Table 4). The opposite response was
observed among subjects with low CFH risk alleles and high
ARMS2 risk alleles (GTG3; n = 238) (Fig. 5 and SI Appendix,
Table 2). These subjects had a significant reduction in AMD
progression risk if treated with the AREDS formulation.
Fig. 2. Bootstrapping schema involving GTG2 and GTG3 subjects from the
combined dataset. The number of selections from the expanded set of subjects
is the same as the number of available subjects in this series of analyses (412).
This selection forms an iteration specific bootstrap discovery set, which con-
tains duplicates because each selected case is returned to the pool before the
subsequent case is selected (“replacement”). Subjects not selected at least once
for the discovery set are then assigned to the bootstrap validation set (152 on
average). A Cox prediction model is generated from the discovery set and
tested against the validation set, generating a concordance index. This entire
procedure of selection, model derivation from the bootstrap discovery set, and
bootstrap set validation is repeated 100 times and the C indices for models
built on the same covariates are averaged. To generate 95% confidence in-
tervals, the bootstrap process based on 100 resamplings was repeated
1,000 times. The red arrow shows the order of the process. The C index reflects
the predictive power of the Cox covariates. Models including covariates with
superior predictive ability will have a higher C index. The addition of un-
informative covariates will not result in higher C indices, and will often lower
predictive accuracy.
Table 3. Hazard ratios of AREDS formulation treatment for
progression to NV or central GA in four genotype groups (with P
values), and P values of tests for interaction of genotype group
and AREDS formulation treatment effect for the expanded
dataset (n = 802)
Genotype group
AREDS-NV AREDS-GA
HR P value HR P value
GTG1 1.41 0.43 0.70 0.40
GTG2 2.92 0.018 1.04 0.93
GTG3 0.50 0.008 0.60 0.09
GTG4 1.03 0.91 0.88 0.74
Interaction (χ2, 2 df) — 0.01 — 0.62
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Discussion
Our analyses of the most comprehensive collection of AREDS
data and DNA to date show that the risk of progression from
intermediate to neovascular AMD is significantly altered by
AREDS formulation treatment in a genotype group-dependent
fashion, confirming prior independent reports of a significant
interaction between AREDS formulation treatment, genetic risk,
and progression to advanced AMD (11, 12).
Klein et al. (10) first observed that the benefit of the AREDS
formulation was eliminated for subjects with high-risk CFH alleles.
The authors postulated that this effect was due to the high-dose
zinc component of the AREDS formulation. Awh et al. (12) an-
alyzed the response to AREDS nutritional supplements as influ-
enced by CFH and ARMS2 genetic risk in 989 AREDS subjects
and confirmed the observation of Klein et al. with regard to CFH,
while identifying an opposite interaction with ARMS2 polymor-
phisms. Subjects with high CFH and low ARMS2 risk alleles had
increased AMD progression if treated with zinc (alone, or as a
component of the AREDS formulation), while those with low
CFH and high ARMS2 risk alleles had decreased progression (13).
Chew et al. (14) published a statistical analysis of 1,237 AREDS
subjects and found no influence of genetics on response to the
AREDS formulation. However, their analyses were performed
separately on 27 relatively small genetic risk–treatment groups, a
design statistically underpowered to demonstrate any interaction.
Seddon et al. (11) analyzed progression to overall advanced AMD
and progression to the two subtypes of advanced AMD, NV and
central GA. They found that for subjects with low CFH and high
ARMS2 genetic risk, the reduction in overall advanced AMD was
due to decreased progression to NV, with no significant effect on
central GA progression. These authors concluded that “the ef-
fectiveness of antioxidant and zinc supplementation appears to
differ by genotype” (11). Their approach differs from ours in that
they considered all subjects regardless of baseline AMD status,
used a single eye as a unit of observation, considered a single SNP
to tag a CFH region rather than the two-SNP-based haplotype we
use, and did not analyze the GTG2 group separately. Despite
these differences, they also concluded that the genetics–treatment
interaction predicts progression to NV and not to central GA.
We assembled a dataset derived from the MMAP archive,
Coriell samples, and NIH Office of Intramural Research Integrity
and Compliance. We performed two validation studies to address
the potential of overfitting and spurious findings in previous
studies: (i) a bootstrap predictive validation of genetics–treatment
interaction model; and (ii) validation of the results in a unique
validation subsample that does not include subjects used pre-
viously in defining genotype groups. Our analysis of this expanded
dataset supports prior observations that the effect of AREDS
formulation treatment on progression to advanced AMD is driven
by changes in the risk of developing NV, not by changes in the risk
of developing central GA. We confirm that individuals with high
CFH and no ARMS2 risk alleles have an increased risk of pro-
gression to NV if treated with the AREDS formulation compared
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Fig. 3. Cox-derived survival curves using expanded datasets for NV-free survival for subjects with high CFH and no ARMS2 risk alleles (GTG2; n = 107) (Left)
and for individuals with low CFH and high ARMS2 risk (GTG3; n = 305) (Right). Subjects in both panels were treated with either placebo or the AREDS
formulation.
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with placebo. For individuals with low CFH and high ARMS2 risk
alleles, we found a substantial beneficial effect from AREDS
formulation treatment. These findings are consistent with those of
Awh et al. (12) and Seddon et al. (11), even though our analysis
differed from theirs in the following ways: (i) We considered
progression to NV as the relevant event rather than progression to
0.20
0.25
0.30
3 4 5 6 7
time
So
m
er
s 
D
xy Model
Interactive
Additive
Base
Fig. 4. A 0.632 bootstrap analysis of GTG2 and GTG3 subjects from the expanded dataset (n = 412) showing superior prediction of NV progression for the
interaction model. Somers’ Dxy (a calibrated C-index measure) for three different Cox proportional hazards models was generated across follow-up time
points (x) with approximate pointwise 95% confidence intervals. The interaction model includes sex, smoking, age, AREDS formulation, genetics, and in-
teraction between AREDS formulation treatment and genetics. The additive model includes all of the covariates in the interaction model, but does not allow
for interaction. The base model considers only sex, smoking, age, and genetics as covariates.
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either NV or central GA; and (ii) we restricted analysis to subjects
treated with either the AREDS formulation or placebo. The de-
cision to analyze progression to only NV is supported by published
evidence that the AREDS formulation is effective only in the
prevention of the NV form of advanced AMD (original AREDS
reports 8 and 35) (8, 9) and by our analysis of the interaction of
GTG and progression to NV or central GA (Table 2). Insensitivity
to this clinical distinction contributed to an inaccurate conclusion
by Assel et al. (27) that the AREDS formulation is beneficial in
genetically unselected individuals. This contributed to their in-
ability to show that individuals in GTG2 treated with the AREDS
supplementation have an increased risk of progression to NV. We
also decided to analyze only those subjects treated with either the
AREDS formulation or placebo, excluding those treated with only
antioxidants or only zinc, to focus our analysis on the “real-world”
decision confronting most patients and physicians: to treat or to
not treat.
Our validation analysis of a unique subgroup of AREDS for-
mulation- or placebo-treated subjects also confirms the genetics–
treatment interaction found by Seddon et al. and Awh et al. (11,
12). This is a group of subjects whose data had not been used to
derive the prespecified genotype groups, hence eliminating the
potential for data overfitting and spurious findings (12). Our
analysis differs from a report by Chew et al., in which the authors
were unable to validate the findings of Awh et al. (12, 18). The
number of relevant cases in our validation dataset is larger be-
cause of the additional cases available through MMAP. We also
evaluated progression only to NV and not to central GA, since
progression to central GA has not been shown to be affected by
supplementation in the original AREDS study.
As a second form of validation, we performed a bootstrap
analysis of genetics–treatment interaction by comparing the pre-
dictive ability of a model that considers genetics–treatment in-
teraction with models that do not. This validation is distinct and
more stringent than the conclusions derived from a Cox model
fitted to a single sample. Spurious covariates identified in a deri-
vation dataset would not improve the prediction of the outcome of
subjects external to the derivation dataset, regardless of their
initial apparent statistical significance. In this sense, bootstrap
validation could be used more broadly to help identify important
interactions, although here we use it strictly to help confirm the
significance of a previously suggested genetics–treatment in-
teraction. Our bootstrap predictive validation illustrates the clin-
ical significance of treatment and genetics interaction in predicting
Table 4. Hazard ratios and P values (Wald) for genotype group
and treatment with the AREDS formulation vs. placebo on the
development of NV for the 299 subjects in the unique set (12)
Genotype group HR AREDS vs. placebo P value
GTG2 4.9 0.021
GTG3 0.36 0.003
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Fig. 5. Cox model-derived survival curves of NV-free survival for unique set subjects with high CFH risk alleles and no ARMS2 risk alleles (GTG2; n = 39) (Left)
and low CFH risk alleles and high ARMS2 risk alleles (GTG3; n = 121) (Right). Subjects were treated with placebo or the AREDS formulation.
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the risk of progression events in new subjects. We considered
three competing models that each attempts to explain the risk of
progression to NV. The base model includes genetics, smoking,
age, and sex as predictors of AMD progression. The additive
model adds the effect of AREDS formulation treatment but does
not allow any effect modification by genetics on AREDS treat-
ment (i.e., excludes the possibility of interaction). The interaction
model builds on the additive model by allowing a genetics–
AREDS formulation treatment interaction. Remarkably, the ad-
ditive model shows only a negligible improvement in prediction
ability over the base model, despite the addition of information
regarding AREDS formulation treatment status. When the ge-
netics–AREDS formulation treatment interaction effect is
allowed, the interaction model shows significant improvement in
accuracy (Fig. 4). We see that the predictive accuracy for all
three models is similar in earlier years, diverging at and beyond
4 y post randomization. This suggests that any treatment effect
accrues over time. The superior predictive performance of the
interaction model confirms that the effectiveness of AREDS
formulation treatment is dependent upon CFH and ARMS2
genetic risk status. The conclusions from this primary bootstrap
analysis on all subjects also hold when the analysis is performed
only within the unique set [i.e., subjects not analyzed by Awh
et al. (12)], further demonstrating that the previously defined
genotype groups and their interactions with treatment were not
spurious effects.
The clinical utility of this observation is illustrated when pro-
gression is considered as a function of genetics using Cox survival
estimates (Fig. 3), which shows that one genotype group (GTG2)
is likely harmed by treatment with the AREDS formulation, while
the other (GTG3) is likely to substantially benefit from treatment.
It appears that the overall modest benefit of the AREDS for-
mulation is the result of effects in a genotype group that does
extraordinarily well, a genotype group that does worse than with
placebo, and subjects whose outcome is relatively unaffected by
treatment with the AREDS formulation (GTG1 and GTG4).
While the AREDS study defined AMD as a posterior pole
disease, it may not be strictly limited to the posterior pole, as
drusen and peripheral pigmentary changes are common in the
periphery of AMD eyes (28, 29). Genetic associations with pe-
ripheral phenotypes (30, 31) further suggest that AMD may not
be limited to posterior pathology and, if confirmed, could also be
valuable in helping determine the appropriate prophylactic nu-
tritional formulation for an expanded number of AMD patients.
The human retina concentrates zinc, with levels influenced by
chronic oral zinc supplementation (32). Biochemical analysis of the
interaction of complement proteins and zinc shows concentration-
dependent oligomerization or insolubility, suggesting a potential
defense against uncontrolled activation (33–36). Pathologic varia-
tions in complement components may interact with zinc. For in-
stance, an AMD-associated polymorphism in complement
component 3 impedes binding to its inhibitor, complement factor
H, preventing the formation of a complex highly sensitive to zinc-
induced inactivation (37). AMD-associated CFH allotypes are less
able to inactivate C3b due to impeded binding to the acute-phase
reactant C-reactive protein, which bridges these two inflammatory
regulators (34). Through such mechanisms, polymorphisms in CFH
may alter the normal role of zinc inactivation of the complement
cascade and may provide the physiologic basis for our observations.
Our observations regarding genetic risk, AMD, and treatment
with the AREDS formulation are based upon multiple statistical
analyses of DNA and data from one of the largest groups of
AREDS subjects yet assembled. They confirm the existence of a
genetics–treatment interaction identified by multiple independent
researchers (10–12). They validate that the response to AREDS
formulation treatment varies substantially among individuals,
based on CFH and ARMS2 genetic risk. They show that the ge-
notype groups previously reported may be an effective method of
identifying individuals who are likely to benefit, or not, from
treatment (12). There is no placebo-controlled replication study of
the AREDS to be used for additional validation. However, the
lack of a replication trial has not prevented the widespread ac-
ceptance and recommendation of the AREDS formulation
treatment for subjects with intermediate AMD. Bootstrap valida-
tion demonstrates that the genetics–treatment interaction is con-
sistent and valid within this dataset, providing support for the
clinical validity of the interaction of CFH and ARMS2 genotype
groups with AREDS formulation treatment.
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